Nanofàrmacs

CATIONIC LIPID

Resumen de: US2025197343A1

The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and/or to various cells and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the formula (I) or a salt thereof. In the formula (I), W represents —NR1R2 or —N+R11R12R13(Z−), R1 and R2 each independently represent H or an optionally substituted C1-5 alkyl group, R11, R12 and R13 each independently represent an optionally substituted C1-5 alkyl group, Z− represents an anion, X represents an optionally substituted C2-6 alkylene group, RA and RB each independently represent an optionally substituted C1-17 alkyl group, an optionally substituted C3-17 alkenyl group, an optionally substituted C15-17 alkadienyl group, —R3—C(O)O—R4 or —R3—OC(O)—R4, RC represents —R3—C(O)O—R4 or —R3—OC(O)—R4, R3 represents an optionally substituted C1-16 alkylene group, an optionally substituted C4-16 alkenylene group or an optionally substituted C7-16 alkadienylene group, and R4 represents H, an optionally substituted C1-18 alkyl group, an optionally substituted C3-18 alkenyl group or an optionally substituted C15-18 alkadienyl group.

METHOD FOR GROWTH OF AKKERMANSIA MUCINIPHILA COMPRISING ADMINISTERING PLATINUM NANOPARTICLES

Resumen de: US2025195563A1

This invention is to provide the novel composition that grows Akkermansia muciniphila in the intestinal microflora. The composition for the growth of Akkermansia muciniphila containing platinum nanoparticles as an active ingredient.

LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS, AND METHOD FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS USING SAME

Resumen de: US2025195429A1

The present invention provides lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells that can improve the efficiency of nucleic acid delivery to peripheral blood mononuclear cells, and a method for delivering nucleic acid to peripheral blood mononuclear cells by using same. Lipid nanoparticles for use in delivering a nucleic acid to a peripheral blood mononuclear cell, containing an ionic lipid represented by the formula (1), a phospholipid that is 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups have not less than 20 carbon atoms and at least one of the acyl groups is an alkenoyl group, cholesterol, and a dimyristoylglycerol PEG represented by the formula: CH2(OR6)—CH(OR7)—CH2(OR8) (symbols in the formula are as described in the specification), and a method for delivering a nucleic acids to a peripheral blood mononuclear cell by using same.

LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE, KIT CONTAINING LIPID PARTICLE, AND ACTIVE AGENT DELIVERY METHOD USING LIPID PARTICLE

Resumen de: US2025195430A1

Provided are a lipid particle with high biodegradability, high biocompatibility, a high active agent introducibility, low cytotoxicity, and the like, a composition and a kit which use the lipid particle, and a method of delivering an active agent to a cell.The lipid particle according to the present embodiment comprises:a compound represented by the following Formula (a),Mal-La1-(OCH2CH2)na—O-La2Ra2  (a)(in the formula,Mal is a maleimide group,La1 is an unsubstituted hydrocarbon group, or a substituted hydrocarbon group,La2 is a trivalent hydrocarbon group that does not contain phosphorus,Ra's are a hydrocarbon group containing at least one ester bond at a predetermined position, andna is a number of 1 or more); andan active agent.

PEPTIDE-BASED PHOSPHATE BINDER FOR THE TREATMENT OF HYPERPHOSPHATEMIA

Resumen de: US2025195687A1

Provided herein are silica nanoparticles conjugated to a phosphate binding hexapeptide (PBH) via a linker amino acid residue and methods of making the same. Further provided are compositions including the nanoparticles and uses thereof in the treatment of hyperphosphatemia.

CONTINUOUS SPIN FREEZE-DRYING OF NUCLEIC ACID CONTAINING COMPOSITIONS

Resumen de: US2025195437A1

The present invention relates to the field of freeze-drying compositions, in particular nucleic acid containing compositions. More specifically, the present invention relates to freeze-dry nucleic acid containing compositions using a method of continuous spin freezing and continuous spin drying (sublimation and desorption) the composition. The invention further relates to a nucleic acid containing composition by making use of the method according to the invention.

POLYMER-COATED NANOPARTICLES AND PREPARATION METHOD THEREFOR

Resumen de: US2025195444A1

Polymer-coated nanoparticles and a preparation method therefor. The structural makeup of the polymer nanoparticles is: a hydrophilic aggregate inner core and a polymer molecular material coating containing a polyoxyethylene structural unit. The hydrophilic aggregate inner core comprises the following preparatory raw materials: a cationic component and an anionic component, the cationic component being a cation, a compound which can be ionized into a cation, or a composition thereof, and the anionic component being an anion, a compound which can be ionized into an anion, or a composition thereof.

NOVEL BIONIC NANOSPHERE M@P-WI AND ITS PREPARATION METHOD AND APPLICATION

Resumen de: US2025195447A1

A novel biomimetic nano-sphere M@P-WI includes PLGA nanoparticles and the membrane of breast cancer EO771 cells. The PLGA nanoparticles are encapsulated within the membrane of breast cancer EO771 cells, and IR780 and DDR2 inhibitor WRG-28 are embedded in the PLGA nanoparticles. A method for preparing and applying the novel biomimetic nano-sphere M@P-WI is also provided. The method utilizes the aforementioned novel biomimetic nano-sphere M@P-WI, to trigger the conversion of light into heat energy upon near-infrared laser irradiation. This “burns” the tumor and induces specific immune responses within the body, inhibiting tumor recurrence and metastasis. Under the action of WRG-28, it promotes apoptosis of cancer-associated fibroblasts (CAF), reduces the remodeling of tumor extracellular matrix microenvironment, enhances the distribution of nanomaterials within the tumor, and restricts the invasiveness of breast cancer cells. With laser irradiation, the photosensitizer exhibits its maximum efficacy, achieving complete elimination of TNBC rich in extracellular matrix.

LIPID NANOPARTICLES COMPRISING CODING RNA MOLECULES FOR USE IN GENE EDITING AND AS VACCINES AND THERAPEUTIC AGENTS

Resumen de: WO2025128871A2

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.

IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF

Resumen de: WO2025128902A1

Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.

CATIONIC LIPID COMPOUNDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2025128696A1

Compounds are provided having the following Formula (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3a, R3b, R3c, R3d, L1, L2, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

LIPID COMPOUNDS AND USES THEREOF

Resumen de: WO2025126113A1

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, L1, L2, R2, R3, a, and b are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

LIPID COMPOUNDS AND USES THEREOF

Resumen de: WO2025126118A1

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERY OF THERAPEUTIC COMPOUNDS

Resumen de: WO2025129128A1

The present disclosure provides compositions and methods for non-viral delivery of therapeutics, and methods of preparing said compositions.

ANTI-HUMAN PD-Ll AND TLR7 DOUBLE-TARGETING NANOBODY CONJUGATE DRUG AND USE THEREOF IN RESISTING TUMOR

Resumen de: US2025197503A1

An anti-human PD-L1 nanobody and use thereof, and an anti-human PD-L1 and TLR7 double-targeting nanobody conjugate drug, a preparation method therefor and use thereof are provided. Specifically, provided are use and a solution of an anti-human PD-L1 nanobody and a derivative protein thereof for anti-tumor treatment, and also provided are design, preparation, and identification solutions for a novel anti-human PD-L1 and TLR7 double-targeting nanobody drug conjugate and a derivative molecule thereof and an effect thereof in anti-tumor treatment. The anti-human PD-L1 and TLR7 double-targeting nanobody drug conjugate can exert significant anti-tumor efficacy.

LONG-LASTING ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE AGENTS AND ANIONIC EXCIPIENTS AND USES

Resumen de: US2025195445A1

This invention refers to long-lasting antibacterial compositions with a broad spectrum of activity, including bactericidal, bacteriostatic, virucidal, virustatic, germicidal, algicidal, fungicidal, and fungistatic activities. These compositions can be used for the production of topical formulations or for environmental treatment, surface disinfection, or dental use. The composition can be in the form of a solution, a moist gel, xerogel, aerosol, spray, polymeric system, or solid state. Specifically, the invention refers to compositions, such as aqueous or alcoholic solutions, or even in gel or powder form, with antibacterial activity. These compositions contain a cationic active (chlorhexidine digluconate, quaternary ammonium, or cetil pyridine) nanoencapsulated in cyclodextrin (alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, hydroxymethyl beta-cyclodextrin, or hydroxypropyl beta-cyclodextrin), which may optionally include alkyl or aryl group insertions, at a molar ratio of 1:1 to 1:4. These compositions also include anionic excipients, as well as humectants, stabilizers, sequestering agents, surfactants, preservatives, or thickeners. Preferably, they include the anionic surfactant sodium lauryl sulfate or the anionic thickener carbomer.

NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS

Resumen de: AU2023392764A1

There is provided a pharmaceutical formulation that is useful in the treatment of metabolic disorders or conditions, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 µm; and (b) comprise solid cores comprising at least one glucagon-like peptide-1 receptor agonist, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is at least about 1:10 and up to and including about 10:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of glucagon-like peptide-1 receptor agonists to treat metabolic disorders or conditions, such as type 2 diabetes and/or obesity without a burst effect. The glucagon-like peptide-1 receptor agonist is preferably liraglutide.

GLYCOLIPID COMPOSITIONS

Resumen de: WO2025125385A1

Provided herein are particles and compositions comprising one or more glycolipids and a nucleic acid, wherein the one or more glycolipids are represented by, for example, formula I or a pharmaceutically acceptable salt thereof.

HYDROGEL COMPOSITIONS

Resumen de: WO2025125384A1

The present invention relates to compositions comprising metal-organic framework (MOF) nanoparticle or nanoparticles, methods of preparing said compositions, methods of treatment using said compositions, and uses of said compositions.

STABILIZATION OF LIPID NANOPARTICLE FORMULATIONS

Resumen de: WO2025128958A1

Aspects of the disclosure relate to compositions and methods for improving the stability of lipid nanoparticles (LNPs). In some embodiments, the LNPs comprise one or more active pharmaceutical ingredients (API) encapsulated therein. The disclosure is based, in part, on compositions that directly or indirectly reduce the degradation (e.g., oxidation, hydrolysis, etc.) of one or more lipids components of the lipid nanoparticle. In some embodiments, the compositions comprise a citrate drug product matrix, EDTA drug product matrix, methionine drug product matrix, and/or a tryptophan drug product matrix. The disclosure also provides methods for storing compositions contemplated herein as well as methods for improving the stability of the API.

ヒトパピローマウイルスナノ粒子製剤

Resumen de: EP4420731A2

The present disclosure provides, in some aspects, virus-like particle drug conjugate formulations and use of the conjugates for treating ocular tumors or lesions.

がんの処置において有用なＩＤＯアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物およびその方法

Resumen de: CN118286450A

The present application relates to formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs and methods thereof for the treatment of cancer. Disclosed herein are formulated and/or co-formulated liposomes comprising an IDO prodrug and methods of making the liposomes. The IDO prodrug composition comprises a drug part for inhibiting IDO-1, a lipid part and a connecting unit. The IDO prodrugs may be formulated and/or co-formulated into liposomes to provide a method of treating cancer, immune disorders, and other diseases by utilizing targeted drug delivery vectors.

脂質化合物及び脂質ナノ粒子組成物

Resumen de: ZA202305909B

Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g. nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.

METHODS OF TREATING A CANCER IN AN INDIVIDUAL

Resumen de: WO2025129108A1

The present application, in certain aspects, pertains to methods of treating a cancer in an individual using a composition comprising nanoparticles comprising an mTOR inhibitor (such as sirolimus) and an albumin. In some aspects, the methods are directed to an individual subjected to two or more prior treatments. In other aspects, the methods are directed to a cancer of the adrenal cortex. In certain aspects, provided are methods of reducing the size of a tumor and/ or reducing a tumor-associated fluid accumulation using a composition comprising nanoparticles comprising an mTOR inhibitor (such as sirolimus) and an albumin.

細胞外小胞を充填するための組成物及び方法

Nº publicación: JP2025518685A 19/06/2025

Solicitante:

ヌレキソンバイオロジックリミテッド

Resumen de: CN119300866A

The present invention provides extracellular vesicles (EVs) loaded with a conjugate of an active agent with a hydrophilic compound, such as a carbohydrate, methods of making and loading the EVs, compositions comprising the EVs and uses thereof, and conjugates of an active agent with a carbohydrate that can be loaded into an EV. In one embodiment, the exosome is loaded with a conjugate of siRNA and glucose.